InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process. 

The company announced Monday that it raised a $34 million series B round led by Anzu Partners and hired John Leite, former VP of clinical BD at Illumina Inc. (NASDAQ:ILMN), as CBO. The news comes as the company is preparing to launch its first diagnostic — a liquid biopsy ovarian cancer test — next half. ...